Connect Biopharma (NASDAQ:CNTB) Stock Keeps "Buy" Rating at HC Wainwright

Key Points

• HC Wainwright reaffirmed its “Buy” rating on Connect Biopharma, while analysts overall maintain a “Moderate Buy” consensus with an average price target of $6.14.
• Connect Biopharma shares opened at $0.94, near their 52-week low of $0.85, with the stock well below its 50-day and 200-day moving averages.
• The company reported a quarterly loss of $0.27 per share, beating expectations of a $0.31 loss, while revenue of $2.75 million exceeded the $0.74 million consensus estimate; institutional investors own 58.72% of the stock.

Connect Biopharma (NASDAQ:CNTB - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research report issued on Thursday, Benzinga reports. HC Wainwright also issued estimates for Connect Biopharma's Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

Other equities research analysts have also issued reports about the company. Weiss Ratings raised shares of Connect Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 24th. Oppenheimer dropped their target price on shares of Connect Biopharma to $5.00 and set an "outperform" rating for the company in a report on Tuesday, September 22nd. Wall Street Zen raised shares of Connect Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. BTIG Research dropped their target price on shares of Connect Biopharma to $5.00 and set a "buy" rating for the company in a report on Wednesday, September 30th. Finally, Canaccord Genuity Group dropped their price objective on shares of Connect Biopharma from $7.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, September 16th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $6.14.

Connect Biopharma Price Performance

Shares of CNTB opened at $0.94 on Thursday. The firm has a market cap of $59.49 million, a PE ratio of -0.79 and a beta of -0.16. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $1.83 and a two-hundred day simple moving average of $2.23. Connect Biopharma has a 1-year low of $0.85 and a 1-year high of $3.82.

Connect Biopharma (NASDAQ:CNTB - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. The company had revenue of $2.75 million during the quarter, compared to analysts' expectations of $0.74 million. On average, equities analysts anticipate that Connect Biopharma will post -1.09 EPS for the current year.

Institutional Trading of Connect Biopharma

Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE bought a new position in shares of Connect Biopharma during the 1st quarter worth $41,000. ADAR1 Capital Management LLC bought a new position in shares of Connect Biopharma during the 1st quarter worth $1,945,000. Knott David M Jr grew its position in shares of Connect Biopharma by 93.9% during the 1st quarter. Knott David M Jr now owns 387,835 shares of the company's stock worth $1,016,000 after buying an additional 187,835 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Connect Biopharma during the 1st quarter worth $135,000. Finally, Richmond Brothers Inc. bought a new position in shares of Connect Biopharma during the 4th quarter worth $489,000. Institutional investors own 58.72% of the company's stock.

About Connect Biopharma

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.